ArticleDiabetes, obesity & metabolism2023
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function.
Article in Diabetes, obesity & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.Diabetes, obesity & metabolism · 2025Trial
- Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes.Cardiovascular diabetology · 2023Trial
- Associations between accelerometer-measured physical activity, sedentary behaviour and pericardial adiposity: a prospective cohort study of UK Biobank participants.BMJ public health · 2026Article
- Beyond Traditional Risk Factors: Integrating Epicardial Adipose Tissue into the Comorbidity Landscape of HFpEF.Journal of clinical medicine · 2025Review
- Epicardial Adipose Tissue and Liver Fibrosis in Patients With Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Liver Disease.Reviews in cardiovascular medicine · 2025Article
- Advancing Cardiovascular Risk Stratification and Functional Assessment: A Narrative Review of CPET and ESE Applications.Healthcare (Basel, Switzerland) · 2025Review
- Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.Cardiovascular diabetology · 2025Review
- Epicardial adipose tissue: a new link between type 2 diabetes and heart failure-a comprehensive review.Heart failure reviews · 2025Review
- Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF.Cardiovascular diabetology · 2025Review
- Potential Mechanisms of Epicardial Adipose Tissue Influencing Heart Failure with Preserved Ejection Fraction.Reviews in cardiovascular medicine · 2024Review
- Obesity: the perfect storm for heart failure.ESC heart failure · 2024Review
- Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?World journal of diabetes · 2024Article
- Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial.Cardiovascular diabetology · 2024Article
- Epicardial fat and Stage B heart failure among overweight/obese and normal weight individuals with diabetes mellitus.The international journal of cardiovascular imaging · 2023Article
- Prognostic value of ventricle epicardial fat volume by cardiovascular magnetic resonance in chronic heart failure.iScience · 2023Article
- Proteomic profiling of epicardial fat in heart failure with preserved versus reduced and mildly reduced ejection fraction.Journal of cellular and molecular medicine · 2023Article
- Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes.Diabetes, obesity & metabolism · 2023Article
- Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function.Diabetes, obesity & metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the impact of epicardial adipose tissue (EAT) thickness on cardiopulmonary performance in patients with type 2 diabetes (T2D) and normal heart function. MATERIALS AND
methodsWe analysed EAT thickness in subjects with T2D and normal biventricular systo-diastolic functions undergoing a maximal cardiopulmonary exercise test combined with stress echocardiography, speckle tracking and pulmonary function assessment, as well as serum N-terminal pro B-type natriuretic peptide (NT-proBNP).
resultsIn the 72 subjects enrolled, those with EAT thickness above the median (> 5 mm) showed higher body fat mass, smaller indexed left ventricular dimensions and marginally reduced diastolic function variables at rest. Higher EAT thickness was associated with lower peak oxygen uptake (VO
conclusionHigher EAT thickness in T2D is associated with worse cardiopulmonary performance and multiple traits of subclinical cardiac systolic dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.